Clinical Trial Update: A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating lecanemab in early Alzheimer's disease has completed and posted results, reporting safety, tolerability, and efficacy findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LEQEMBI (lecanemab)

Snippet

Sponsor: Eisai Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2026-03-04